Ami Vyas1, Frisca Kang2, Marilyn Barbour2. 1. Department of Pharmacy Practice, College of Pharmacy, University of Rhode Island, 7 Greenhouse Road, Kingston, RI, 02881, USA. avyas@uri.edu. 2. Department of Pharmacy Practice, College of Pharmacy, University of Rhode Island, 7 Greenhouse Road, Kingston, RI, 02881, USA.
Abstract
PURPOSE: There are known associations between cardiometabolic risk factors and polypharmacy; however, there is no evidence about how polypharmacy among adults with cardiometabolic risk factors impacts their health-related quality of life (HRQoL). The main objective of this study was to assess the association between polypharmacy and HRQoL among adults with cardiometabolic risk factors living in the USA. METHODS: Individuals age ≥ 18 years with at least one of the three cardiometabolic risk factors (diabetes, hyperlipidemia, and hypertension) were identified from the Medical Expenditure Panel Survey 2015 data. We defined polypharmacy as use of at least five classes of prescription medications. Physical component summary (PCS) and mental component summary (MCS) were obtained from the 12-item Short-Form Health Survey version 2 to measure HRQoL. We conducted adjusted ordinary least-square regressions to determine the association between polypharmacy and HRQoL. RESULTS: We identified 7621 (weighted N = 80 million) adults with at least one cardiometabolic risk factors of whom 46.9% reported polypharmacy. Polypharmacy was noted in 29.7% of those with hypertension, whereas 82.4% of those with all the three cardiometabolic risk factors had polypharmacy. The unadjusted mean PCS and MCS scores for those with polypharmacy were lower than those without polypharmacy. In the multivariable regressions, we found that adults with polypharmacy had significantly lower PCS scores (β = - 4.27, p < 0.0001) compared to those without polypharmacy, while the MCS scores between those with and without polypharmacy were no longer significantly different. CONCLUSION: Surveillance of use of concurrent prescription medications is warranted so as to improve physical functioning in this vulnerable group.
PURPOSE: There are known associations between cardiometabolic risk factors and polypharmacy; however, there is no evidence about how polypharmacy among adults with cardiometabolic risk factors impacts their health-related quality of life (HRQoL). The main objective of this study was to assess the association between polypharmacy and HRQoL among adults with cardiometabolic risk factors living in the USA. METHODS: Individuals age ≥ 18 years with at least one of the three cardiometabolic risk factors (diabetes, hyperlipidemia, and hypertension) were identified from the Medical Expenditure Panel Survey 2015 data. We defined polypharmacy as use of at least five classes of prescription medications. Physical component summary (PCS) and mental component summary (MCS) were obtained from the 12-item Short-Form Health Survey version 2 to measure HRQoL. We conducted adjusted ordinary least-square regressions to determine the association between polypharmacy and HRQoL. RESULTS: We identified 7621 (weighted N = 80 million) adults with at least one cardiometabolic risk factors of whom 46.9% reported polypharmacy. Polypharmacy was noted in 29.7% of those with hypertension, whereas 82.4% of those with all the three cardiometabolic risk factors had polypharmacy. The unadjusted mean PCS and MCS scores for those with polypharmacy were lower than those without polypharmacy. In the multivariable regressions, we found that adults with polypharmacy had significantly lower PCS scores (β = - 4.27, p < 0.0001) compared to those without polypharmacy, while the MCS scores between those with and without polypharmacy were no longer significantly different. CONCLUSION: Surveillance of use of concurrent prescription medications is warranted so as to improve physical functioning in this vulnerable group.
Entities:
Keywords:
Cardiometabolic risk factors; Health-related quality of life; Medical Expenditure Panel Survey; Polypharmacy; Regression
Authors: Nancy E Mayo; Nikki Ow; Miho Asano; Sorayya Askari; Ruth Barclay; Sabrina Figueiredo; Melanie Hawkins; Stanley Hum; Mehmet Inceer; Navaldeep Kaur; Ayse Kuspinar; Kedar K V Mate; Ana Maria Moga; Maryam Mozafarinia Journal: Qual Life Res Date: 2022-03-21 Impact factor: 3.440
Authors: Marwan Alrasheed; Jeff Jianfei Guo; Alex C Lin; Patricia R Wigle; Angelica Hardee; Ana L Hincapie Journal: Qual Life Res Date: 2022-01-22 Impact factor: 4.147
Authors: Lisa Van Wilder; Brecht Devleesschauwer; Els Clays; Peter Pype; Sophie Vandepitte; Delphine De Smedt Journal: Prev Chronic Dis Date: 2022-08-18 Impact factor: 4.354
Authors: Kyriakos Souliotis; Theodoros V Giannouchos; Chistina Golna; Evangelos Liberopoulos Journal: Qual Life Res Date: 2021-06-22 Impact factor: 3.440